[
  {
    "ts": null,
    "headline": "These Stocks Lead Dow Jones In February. Hint: It's Not AI Companies.",
    "summary": "As technology, financial and consumer discretionary sectors struggle this year, investors have shifted to an odd mix of economically sensitive sectors such as materials and energy along with consumer staples and utilities.",
    "url": "https://finnhub.io/api/news?id=b18fd21b9bdc7ea889600e4951d6f264ac8cdc50627913010127519864b6cbb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772227839,
      "headline": "These Stocks Lead Dow Jones In February. Hint: It's Not AI Companies.",
      "id": 139256962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "As technology, financial and consumer discretionary sectors struggle this year, investors have shifted to an odd mix of economically sensitive sectors such as materials and energy along with consumer staples and utilities.",
      "url": "https://finnhub.io/api/news?id=b18fd21b9bdc7ea889600e4951d6f264ac8cdc50627913010127519864b6cbb7"
    }
  },
  {
    "ts": null,
    "headline": "Merck Stock, Up 18% In 2026, Ticks Another Box. Is It Now A Buy?",
    "summary": "Merck stock ticked another box Friday after the firm said its Keytruda-containing regimen improved outcomes for ovarian cancer patients.",
    "url": "https://finnhub.io/api/news?id=e70132873a14639f3a30cd085b37ffb70cab93746e2a69c43fca4da558de2ace",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772226436,
      "headline": "Merck Stock, Up 18% In 2026, Ticks Another Box. Is It Now A Buy?",
      "id": 139257074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck stock ticked another box Friday after the firm said its Keytruda-containing regimen improved outcomes for ovarian cancer patients.",
      "url": "https://finnhub.io/api/news?id=e70132873a14639f3a30cd085b37ffb70cab93746e2a69c43fca4da558de2ace"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S",
    "url": "https://finnhub.io/api/news?id=b7735e7988c593e5855b404c5dbaaa4b69f1182b7a4a8898c50b1507c5ace208",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772226149,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 139257032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S",
      "url": "https://finnhub.io/api/news?id=b7735e7988c593e5855b404c5dbaaa4b69f1182b7a4a8898c50b1507c5ace208"
    }
  },
  {
    "ts": null,
    "headline": "Sunrun stock nosedives on outlook, Merck job cuts, Jefferies sinks",
    "summary": "Market Domination host Josh Lipton takes a look at some of Friday's trending tickers and stories. Merck (MRK) announced it will cut staff from one of its HPV vaccine factories. Jefferies (JEF) stock is falling on the company's exposure to a failed finance firm, another blow to the private credit market. Sunrun (RUN) stock is nosediving after the company's cautious outlook disappointed investors. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=fd54aaf2a6882d8c358621c97d061c00485dff31b214f75b6c950ec68317ac37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772225478,
      "headline": "Sunrun stock nosedives on outlook, Merck job cuts, Jefferies sinks",
      "id": 139257076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Market Domination host Josh Lipton takes a look at some of Friday's trending tickers and stories. Merck (MRK) announced it will cut staff from one of its HPV vaccine factories. Jefferies (JEF) stock is falling on the company's exposure to a failed finance firm, another blow to the private credit market. Sunrun (RUN) stock is nosediving after the company's cautious outlook disappointed investors. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=fd54aaf2a6882d8c358621c97d061c00485dff31b214f75b6c950ec68317ac37"
    }
  },
  {
    "ts": null,
    "headline": "What's going on in today's session: S&P500 movers",
    "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.",
    "url": "https://finnhub.io/api/news?id=427105e933423cceb275c4ddf81583d598c33d24fe84d9ffc484c6cb3b253d31",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772222704,
      "headline": "What's going on in today's session: S&P500 movers",
      "id": 139256029,
      "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
      "related": "MRK",
      "source": "ChartMill",
      "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.",
      "url": "https://finnhub.io/api/news?id=427105e933423cceb275c4ddf81583d598c33d24fe84d9ffc484c6cb3b253d31"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Friday Afternoon",
    "summary": "Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the State Street Healt",
    "url": "https://finnhub.io/api/news?id=26499900e1001f4237930815b649ff63f8fc563f2b951ed39ab682bd1801eb33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772218889,
      "headline": "Sector Update: Health Care Stocks Higher Friday Afternoon",
      "id": 139255600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the State Street Healt",
      "url": "https://finnhub.io/api/news?id=26499900e1001f4237930815b649ff63f8fc563f2b951ed39ab682bd1801eb33"
    }
  },
  {
    "ts": null,
    "headline": "Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy?",
    "summary": "Merck stock ticked another box Friday after the firm said its Keytruda-containing regimen improved outcomes for ovarian cancer patients.",
    "url": "https://finnhub.io/api/news?id=7eaafe81cb5e069ce359b156563601f5fc6895df0ce7e634aab28d4282e7ceea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772213334,
      "headline": "Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy?",
      "id": 139254394,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck stock ticked another box Friday after the firm said its Keytruda-containing regimen improved outcomes for ovarian cancer patients.",
      "url": "https://finnhub.io/api/news?id=7eaafe81cb5e069ce359b156563601f5fc6895df0ce7e634aab28d4282e7ceea"
    }
  },
  {
    "ts": null,
    "headline": "Merck Says Keytruda Plus Padcev Decreases Risk of Death in Bladder Cancer Trial",
    "summary": "Merck (MRK) said Friday that a phase 3 trial showed Keytruda plus Padcev decreased the risk of event",
    "url": "https://finnhub.io/api/news?id=1f0637781ddaad77a0fc122306753166eea5982f984e3028eca5e30880402123",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772210388,
      "headline": "Merck Says Keytruda Plus Padcev Decreases Risk of Death in Bladder Cancer Trial",
      "id": 139254395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) said Friday that a phase 3 trial showed Keytruda plus Padcev decreased the risk of event",
      "url": "https://finnhub.io/api/news?id=1f0637781ddaad77a0fc122306753166eea5982f984e3028eca5e30880402123"
    }
  },
  {
    "ts": null,
    "headline": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
    "summary": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
    "url": "https://finnhub.io/api/news?id=fd445e2724625e6a109ff734f0648892f87df7df2e8e983c77c57a0bb579559e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772209080,
      "headline": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
      "id": 139256613,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=fd445e2724625e6a109ff734f0648892f87df7df2e8e983c77c57a0bb579559e"
    }
  },
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer",
    "summary": "RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer reg",
    "url": "https://finnhub.io/api/news?id=0206a2ba08a91b8f2e671f5bcf844c0f08ef04e8545100b148d36c488073f0bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772205300,
      "headline": "KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer",
      "id": 139250010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer reg",
      "url": "https://finnhub.io/api/news?id=0206a2ba08a91b8f2e671f5bcf844c0f08ef04e8545100b148d36c488073f0bd"
    }
  },
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
    "summary": "RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will",
    "url": "https://finnhub.io/api/news?id=5d6e66b9297df10c278ca65cc0a5951491ef9776d2f1e098ce5b819cce440d21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772204400,
      "headline": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
      "id": 139250011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will",
      "url": "https://finnhub.io/api/news?id=5d6e66b9297df10c278ca65cc0a5951491ef9776d2f1e098ce5b819cce440d21"
    }
  },
  {
    "ts": null,
    "headline": "Verizon Leads March's 'Safer' Little Dogs Of The Dow",
    "summary": "Verizon Leads March's 'Safer' Little Dogs Of The Dow",
    "url": "https://finnhub.io/api/news?id=8a8f984f973a7d5c6a44f4f7eaa3f6421694c5b2ab9e8ededbb27ce43ee9f856",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772189324,
      "headline": "Verizon Leads March's 'Safer' Little Dogs Of The Dow",
      "id": 139250021,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8a8f984f973a7d5c6a44f4f7eaa3f6421694c5b2ab9e8ededbb27ce43ee9f856"
    }
  },
  {
    "ts": null,
    "headline": "OPKO Health Q4 Earnings Call Highlights",
    "summary": "OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc",
    "url": "https://finnhub.io/api/news?id=de3bc70686768dfe5f9e5efa067f9c6598800e9e6e5498aafc68873d9e89375f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772172776,
      "headline": "OPKO Health Q4 Earnings Call Highlights",
      "id": 139244673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc",
      "url": "https://finnhub.io/api/news?id=de3bc70686768dfe5f9e5efa067f9c6598800e9e6e5498aafc68873d9e89375f"
    }
  }
]